WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

Bis zum Lunchbreak: https://invest.hket.com/article/2832387/%E3%80%90%E8%B2%A1%E7%B6%93%E7%9B%B4%E6%92%AD%E3%80%91%E5%8A%A0%E6%80%9D%E7%A7%91%E9%A6%96%E6%8E%9B%E5%8D%871%E6%88%90%20%E4%B8%80%E6%89%8B%E8%B3%AC%E9%9D%A2%E8%B3%BA420%E5%85%83 12:19 [Hongkonger Aktien fielen an einem halben Tag um 54 Punkte] Der Hang Seng Index schloss mittags bei 26.444 Punkten, ein Minus von 54,41 oder 0,21%, mit einem Umsatz von 73,1 Milliarden Yuan.  WuXi (02269) stieg um 4,6% als Blue Chip mit der besten Performance, HSBC Holdings (00005) fiel um 4% als schlechtester Blue Chip und schloss mittags bei 39,5 Yuan.

With the Pandemic Fading, the Stars Align for Emerging Market Growth Stocks in 2021 https://www.barrons.com/articles/the-stars-align-for-emerging-market-growth-stocks-in-2021-51608283838?mod=hp_LEADSUPP_1 ... Within China, health care is a new frontier, primed for the kind of explosive growth already seen in e-commerce, Jennison’s Moreno predicts. “China’s health-care spend will easily double from 5% to 10% of GDP,” she says. Picking stocks for this boom isn’t simple. However, she and Columbia’s White both flag Wuxi Biologics (2269.Hong Kong), a market leader in drug testing. ...

👍

Ist das die neue Aktie?

Hong Kong and China markets rise on rally in pharmaceutical stocks, vaccines progress https://amp.scmp.com/business/markets/article/3114276/hong-kong-stocks-see-saw-investors-weigh-optimism-over-us-stimulus The markets in Hong Kong and China were on Thursday boosted by strong rallies in stocks of pharmaceutical companies, as investors bet on certain medicines being included into a list of drugs that China’s official health insurance will cover. The Hang Seng Index, which posted its biggest rally in a month on Wednesday, closed 0.8 per cent higher at 26,678.38. In China, the Shanghai Composite Index advanced by 1.1 per cent to 3,404.87, recording its biggest gain since December 1. Sino Biopharmaceutical led the gains in Hong Kong and rose 7.8 per cent, followed by Wuxi Biologics, which climbed 6.5 per cent. ... State media China Central Television said on Thursday that negotiations between drug makers and officials were wrapped up on Wednesday. The list, which has not yet been made public, is expected to be updated soon. ...

Ja, ist der Chat zur WKN A2QJCN. Hatte ihn nach dem split eröffnet, weil BN kein allgemeines Forum eröffnen wollte.

KYG970081173

Moin ist das hier die aktuelle Wuxi Gruppe oder welche ist die richtige ?? 🤔🤷🏼

.

Hong Kong stocks open (12.17) ︱ Hang Seng Index rose 0.56%, WuXi Biologics (02269) opened nearly 6% higher in early trading https://m.jrj.com.cn/madapter/hk/2020/12/17092531507499.shtml The three major U.S. stock indexes closed mixed overnight. The Federal Reserve kept interest rates unchanged and did not adjust its asset purchase plan. The Dow closed down 0.15%, the Nasdaq rose 0.5%, and the S&P 500 index rose 0.18%. The Nasdaq reached a new closing high. In terms of blue chips, WuXi Biologics (02269) opened 5.85% higher at HK$86.8, with pre-market turnover of 156 million. 

Hong Kong stocks pattern: Guo Jiayao expected to move within a narrow range, WuXi Biologics is the first choice for pharmaceutical stocks https://hk.on.cc/hk/bkn/cnt/finance/20201217/mobile/bkn-20201217103649432-1217_00842_001.html ...The recovery of pharmaceutical stocks was mainly due to the fact that the price drop of medicines caused by the large-volume procurement policy did not imagine CUHK, which caused the stock prices of related companies to rebound recently.   ....   Investors prefer WuXi Biologics ( 02269 ). The company's main focus is on clinical verification. Its business is less affected by the volume purchase policy. It is the industry's first choice.  ...

Investment Outlook for 2021 | A number of leading firms expect the HSI to rise to 29,000. 15 Hong Kong stocks to watch https://www.businesstimes.com.hk/articles/131093/2021-%E6%8A%95%E8%B3%87%E5%B1%95%E6%9C%9B-%E5%8C%AF%E8%B1%90%E7%A7%81%E4%BA%BA%E9%8A%80%E8%A1%8C-%E5%85%89%E5%A4%A7%E6%96%B0%E9%B4%BB%E5%9F%BA-%E5%A4%A7%E6%91%A9-%E9%AB%98%E7%9B%9B-%E6%B8%AF%E8%82%A1 ... Morgan Stanley: Hong Kong stocks rating upgrade to "overweight" calls for attention to 9 Hong Kong stocks Morgan Stanley is optimistic about Hong Kong stocks and upgraded its rating to "Overweight". The Hang Seng Index targets 28,700 points at the end of next year, which is equivalent to 12.5 times the forecast P/E ratio; the HSCEI targets 11,400 points, which is equivalent to 9.3 times the forecast P/E ratio. Morgan Stanley listed 9 Hong Kong stocks, believing that they have sustained competitive advantages, and urged investors to pay attention, including ... and WuXi Biologics. ...

Immutep : Upscales Efti Manufacturing https://www.marketscreener.com/quote/stock/IMMUTEP-LIMITED-38892320/news/Immutep-Upscales-Efti-Manufacturing-32023380/ .... Immutep is planning to increase the efti manufacturing process from 200L to 2,000L capacity bioreactors at the WuXi Biologics manufacturing plant (Mashan site, Wuxi, China), with the major scale up steps taking place throughout 2021. Chris Chen, CEO of WuXi Biologics said: "We are very pleased to be moving the scale up process forward for efti with Immutep. WuXi Biologics and Immutep have been working together for many years and we are excited to continue supporting them as they advance towards registration for efti." Marc Voigt, CEO of Immutep said:"Following the very encouraging interim Overall Survival data announced last week from our largest clinical trial, AIPAC, we have activated our plans to upscale the manufacturing of efti to 2,000L single-usebioreactorsto prepare for potential commercial manufacturing and potential registration trials in multiple indications. WuXi Biologics is an important and long-termpartner for us with excellent technical and commercial capabilities. We are entering 2021 in a very strong position, both financially and operationally."

Macquarie suggests two leading biotech stocks to capture drug stocks after health insurance talks end https://inews.hket.com/article/2829064/%E3%80%90%E5%A4%A7%E8%A1%8C%E9%BB%9E%E7%9D%87%E3%80%91%E9%BA%A5%E6%A0%BC%E7%90%86%E5%BB%BA%E8%AD%B0%E9%86%AB%E4%BF%9D%E8%AB%87%E5%88%A4%E7%B5%90%E6%9D%9F%E5%BE%8C%E6%92%88%E8%97%A5%E8%82%A1%E3%80%80%E9%A6%96%E9%81%B8%E5%85%A9%E9%9A%BB%E9%BE%8D%E9%A0%AD%E7%94%9F%E7%89%A9%E7%A7%91%E6%8A%80%E8%82%A1 Macquarie published a research report stating that the fifth round of medical insurance negotiations (NRDL) was officially held in Beijing. So far, public information is limited. It is estimated that Hengrui Pharmaceuticals, BeiGene (06160) and Junshi Biotech (01877) may discuss PD  -1 The price of drugs has been significantly reduced by 60% to 80%, but imported PD-1 may not be included. It is recommended that investors make a bottom after the medical insurance negotiations. The bank said that the NRDL on the first day did not announce a formal price reduction notice, but the price discussion of the most important PD1 drug may be held on the morning of December 16, and the price reduction is expected to reach 60% to 80%. This is for pharmaceutical companies and biotechnology companies.  The company is expected to have a negative impact. The stock price of the sector has fallen from a high level by about 11% to 13%, which is about 3% lower than the MSCI China Index during the same period. Macquarie expects that pharmaceutical companies and biotechnology companies may still invest more funds in R&D to develop new products to reduce the impact of policies. It is expected that WuXi Biologics (02269) should continue to benefit and give "outperform"  The rating and target price are RMB 87.34. Cinda Bio (01801) is the first choice, with a rating of “Outperform” and a target price of RMB 76.01.

Der Markt bis zum 'Lunch break': Pharmaceutical stocks generally bucked the market... http://www.aastocks.com/tc/stocks/news/aafn-news/RUM.201215_103130/2  Hang Seng Index opened 29 points higher this morning and recovered to 26,436 unsustainable. The U-turn once fell 261 points to a low of 26,127. It is now at 26,259 and continues to pee 130 points or 0.5%; the H-Share Index fell 0.3% to 10,411. However, pharmaceutical-related stocks generally bucked the market this morning.  ... Same is blue chip WuXi Biologics: low as 77.7 yuan and was accepted, and the U-turn was as high as 81.25 yuan, and the current price  was 80.9 yuan, a 3.5% increase. ... According to "China Securities Journal", the fourth batch of national drug procurement in the Mainland kicked off. Some companies quickly announced the risk of price cuts due to the collection of competing products. The report quoted a person in charge of a pharmaceutical company as saying that he is more concerned about the price reduction of high-end generic drugs, which is crucial to the company's future product layout.

Ein relativ langer Bericht und deshalb grob zusammengefasst. Ggf mal selbst durch den Übersetzer jagen: Sino-Thailand International: WuXi Biologics (02269) reached a number of collaborations on innovative tumor treatments, with broad market prospects https://finance.sina.cn/hkstock/ggyw/2020-12-14/detail-iiznezxs6843498.d.html?from=wap The company has reached a number of cooperation in the field of oncology, with a broad market prospect. ... Looking at the strong demand for biopharmaceutical research and development in the medium term, WuXi Biologics, as the industry leader, will continue to benefit According to statistics from the Southern Institute of Pharmaceutical Economics, in the first three quarters of 2020, the revenue and total profits of listed companies in the pharmaceutical industry from the sales of biological preparations increased by 19.8% and 28.2% year-on-year, respectively. The growth rate significantly outperformed other sectors of the pharmaceutical industry, indicating The demand for R&D and production services will also increase, and WuXi Biologics will benefit as the industry leader. Reiterate the "overweight" rating and raise the target price ...